FDA approves second Alzheimer’s treatment

from POLITICO's Pulse Check · host POLITICO

On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode metadata supplied by the publisher feed · Published Jan 9, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

FDA approves second Alzheimer’s treatment

0:00 8:12

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of POLITICO's Pulse Check?

This episode is 8 minutes long.

When was this POLITICO's Pulse Check episode published?

This episode was published on January 9, 2023.

Can I download this POLITICO's Pulse Check episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!